Adragos Hub

Contents What Defines a High-Potency Active Pharmaceutical Ingredient Programme? Occupational Exposure Classification and Containment Strategy Small Molecule Formulation Expertise Analytical Development and Method Validation Technology Transfer and Scale-Up Readiness Regulatory and Good Manufacturing Practice Compliance Integration Across the Development-to-Supply Pathway […]

CPHI (Convention on Pharmaceutical Ingredients) is the leading global gathering for the pharmaceutical industry. It brings together research, development and manufacturing experts to forge partnerships that drive new therapies and innovations for patients everywhere. Covering the full supply chain, from […]

How to Assess Pre-Filled Syringe CDMO Readiness Contents What Makes a CDMO Ready for Pre-Filled Syringe Technology Transfer? Aseptic Fill-Finish Infrastructure Container Format Compatibility and Platform Syringe Systems Automated Inspection and Zero-Defect Quality Standards Regulatory Certification and Multi-Market Readiness Commercial […]

For commercial pre-filled syringe manufacturing in Europe, a CDMO should combine five essential capabilities: proven sterile fill-finish expertise, prefilled syringe and device know-how, validated commercial-scale capacity, mature European GMP quality systems, and robust release testing and supply continuity. These capabilities […]

Sterile fill-finish capacity is one of the most critical outsourcing decisions in injectable drug development. For pharmaceutical and biotech companies, the challenge is not only to find a contract manufacturer able to fill a Phase I clinical batch. The real […]

Adragos Pharma is pleased to confirm its participation in the 14th Antibody Industrial Symposium (AIS2026), taking place in Montpellier, France. Organised by MabDesign and MabImprove, AIS2026 brings together leading players across the antibody and biologics value chain — from discovery […]